Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | DHFR | P00374 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 4/20 | 0.50 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PNMT | P11086 | 1/20 | 0.45 |
| ▸ | CLPP | Q16740 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17985055 | 0.86 | KMT2A (0.67) | KMT2AMEN1RAB9ANPC1DHFR | |
| SCHEMBL31647697 | 0.81 | KMT2A (0.60) | KMT2AMEN1RAB9ANPC1DHFR | |
| SCHEMBL29883119 | 0.81 | KMT2A (0.63) | KMT2AMEN1RAB9ANPC1DHFR | |
| SCHEMBL1038680 | 0.81 | KMT2A (0.63) | KMT2AMEN1RAB9ANPC1DHFR | |
| SCHEMBL17984895 | 0.79 | MEN1 (0.55) | KMT2AMEN1RAB9ANPC1DHFR | |
| SCHEMBL2110909 | 0.79 | KMT2A (0.43) | KMT2AMEN1RAB9ANPC1DHFR | |
| SCHEMBL6606580 | 0.78 | MEN1 (1.00) | KMT2AMEN1RAB9ANPC1DHFR | |
| SCHEMBL28169331 | 0.77 | MEN1 (0.61) | KMT2AMEN1RAB9ANPC1DHFR | |
| SCHEMBL30474383 | 0.76 | MEN1 (0.51) | KMT2AMEN1RAB9ANPC1DHFR | |
| SCHEMBL17984846 | 0.76 | MEN1 (0.54) | KMT2AMEN1RAB9ANPC1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300986-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD (CN) | 2024-09-12 | — | — | US | disclosed |
| US-20240124443-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD (CN) | 2024-04-18 | — | — | US | disclosed |
| EP-4289850-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Scinnohub Pharmaceutical Co., Ltd (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289850-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Scinnohub Pharmaceutical Co., Ltd (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-4273135-A1 | PLASMIN INHIBITOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Scinnohub Pharmaceutical Co., Ltd (CN) | 2023-11-08 | — | — | EP | disclosed |
| EP-4273135-A1 | PLASMIN INHIBITOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Scinnohub Pharmaceutical Co., Ltd (CN) | 2023-11-08 | — | — | EP | disclosed |
| CN-116848122-A | Plasmin inhibitor, preparation method and application thereof | 赛诺哈勃药业（成都）有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116710440-A | Plasmin inhibitor, preparation method and application thereof | 赛诺哈勃药业（成都）有限公司 | 2023-09-05 | — | — | CN | disclosed |
| WO-2022166845-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 赛诺哈勃药业（成都）有限公司 | 2022-08-11 | — | — | WO | disclosed |
| WO-2022143911-A1 | PLASMIN INHIBITOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 赛诺哈勃药业（成都）有限公司 | 2022-07-07 | — | — | WO | disclosed |
| CN-108368107-B | Fused heterocyclic compounds as S1P modulators | 艾伯维公司 | 2021-11-26 | — | — | CN | disclosed |
| US-10556907-B2 | Fused heterocyclic compounds as S1P modulators | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-02-11 | — | — | US | disclosed |
| US-10556907-B2 | Fused heterocyclic compounds as S1P modulators | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-02-11 | — | — | US | disclosed |
| EP-3341369-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017036978-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | ABBVIE INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20170057966-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20170057966-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20170057966-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057966-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | S1PR1, S1PR2, S1PR3 | KMT2A 3227/4885MEN1 1839/4885RAB9A 2001/4885 |
| US-20240124443-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | F2, PLG, PLAT | KMT2A 2898/4885MEN1 726/4885RAB9A 3346/4885 |
| US-20240300986-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | F2, PLG, PLAT | KMT2A 3791/4885MEN1 993/4885RAB9A 3400/4885 |
| US-10556907-B2 | Fused heterocyclic compounds as S1P modulators | S1PR1, S1PR2, S1PR3 | KMT2A 3227/4885MEN1 1839/4885RAB9A 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.